VYNE logo

VYNE THERAPEUTICS INC

VYNENASDAQ
US Equity
$791.29▲ $52.62 (+6.65%)
Simulated price
🔔
Track VYNE
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 6.7%
7d▲ 3047.5%
14d▲ 3047.5%
30d▲ 3047.5%
ytd▲ 2628.6%
1y▲ 4710.3%
🏦Market Cap
$218.82B
Large Cap
📈Revenue Growth (YoY)
+111.0%
High Growth
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
158.1x
Expensive
Otter Score
80
Good

Trading Snapshot

Day Range
$787.29 – $794.56
52-Week Range
$15.78 – $46.95
Volume
$2.63B
Avg Volume
$3.29B
Shares Outstanding
—
Next Earnings
Oct 22, 2026

Fundamentals Snapshot

Annual Revenue
$570,000
Last Q Revenue
$570,000
P/E Ratio
—
P/S Ratio
158.1x
EPS (TTM)
—
Dividend Yield
—
Dilution (1yr)
+0.4%

Why Investors Own VYNE

  • ✓High-growth profile — revenue up +23.1% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 66% gross margin and 5% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

VYNE logo

VYNE THERAPEUTICS INC

VYNE
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$570K▲ +13.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
96.0%▼ −4.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$30M▼ −31.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$33M▼ −2.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
855K▲ +0.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$24M▲ +$4M YoY
StockOtter · stockotter.space

About VYNE THERAPEUTICS INC

VYNE Therapeutics Inc. is a pharmaceutical enterprise dedicated to discovering and advancing therapies for immune-mediated inflammatory conditions. Its development portfolio features FCD105, a topical foam formulation that has successfully finished Phase III clinical studies for the management of moderate-to-severe acne vulgaris. Another candidate in its pipeline is FMX114, a combination treatment incorporating tofacitinib, which is currently in early-stage clinical assessment, referred to as a Phase IIa preclinical trial, for addressing mild-to-moderate atopic dermatitis. Additionally, the company is progressing VYN201, a bromodomain and extra-terminal (BET) inhibitor designed to target a range of immuno-inflammatory disorders, notably those affecting the skin. A further asset is VYN202, which comprises BET inhibitor compounds engineered for selective action on bromodomain 2. Established in 2003, the firm was formerly recognized as Menlo Therapeutics Inc. before officially changing its corporate identity to VYNE Therapeutics Inc. in September 2020. The company's principal operations are based in Bridgewater, New Jersey.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
80/100

Analyst Price Target

ⓘ
Average Target
$777.34
▼ −1.8% Downside
High Target$933.35
Low Target$674.13
Based on 29 analysts

Latest News & Updates

🚀
Reuters·2h ago

VYNE THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift VYNE price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

VYNE THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.